The study analyzed health records from Spain and Norway covering more than 150,000 women, including detailed information on whether they had received cabergoline to suppress milk production. Women who took the medication were around 70 percent less likely to develop breast cancer in the years that followed compared with those who did not receive the drug. While observational data of this kind cannot by itself prove causation, the strength of the association, its consistency across two independent national health systems, and its alignment with experimental evidence in animals give the result unusual weight for an early-stage prevention finding.

The mouse experiments provided the biological plausibility that population data alone cannot. When the researchers gave a single dose of cabergoline to mice carrying mutations in the BRCA1 and TP53 genes, both of which are linked to aggressive, difficult-to-treat forms of breast cancer, tumor incidence rates fell by approximately half. The treated animals also showed less potentially precancerous tissue, a smaller ductal area within the mammary gland, reduced cell proliferation, and an increase in immune cells responsible for clearing out damaged cells. Together, these effects point to a coherent mechanism: the drug appears to help the breast finish a natural remodeling process that, when incomplete, can leave dangerous cells behind.

That process is called involution, and it is one of the least discussed but most consequential events in breast biology. After a woman stops breastfeeding, the milk-producing structures that expanded during pregnancy are no longer needed, and the breast undergoes a major cleanup to remove the excess tissue. Study co-lead Dr. Christopher Maxwell, a professor in the University of British Columbia’s faculty of medicine and an investigator at BC Children’s Hospital Research Institute, compares the process to a fruit tree preparing for winter. In spring and summer the tree grows branches, produces blossoms and eventually fruit; once the fruit is gone, it sheds what it no longer needs and resets for the next season. During pregnancy, rising hormone levels cause the milk-producing structures within the breast to branch out into a ductal tree, and once breastfeeding ends, involution prunes that tree back.

The trouble, the researchers found, is that this cleanup can be incomplete. In their experimental mice, involution sometimes stalled, leaving behind cells that retain the potential to become cancerous. This matters because the postpartum period is already recognized as a vulnerable window: breast tissue is dense with recently expanded cell populations, and any cells carrying mutations that survive the cleanup have had a fresh opportunity to accumulate damage during pregnancy itself. Epidemiologists have long observed a transient increase in breast cancer risk in the years immediately following childbirth, particularly among younger women and those with inherited cancer predisposition, before the long-term protective effects of pregnancy eventually take hold.

Cabergoline appears to tip that balance. By accelerating the breast’s natural post-weaning transition, the drug seems to push involution to completion, sweeping away the residual cells that would otherwise linger as seeds of future malignancy. In the mouse studies this translated into measurably less precancerous tissue and stronger immune surveillance of damaged cells. The drug itself is not new: it is an established dopamine receptor agonist, generally well tolerated by patients with few side effects, and already approved by regulatory agencies including Health Canada and the European Medicines Agency for lactation suppression and other indications. That existing approval could substantially shorten the path to clinical use as a preventive agent if trial results are positive.

The clinical stakes are considerable. Breast cancer is the leading cause of cancer-related death among younger women, and the majority of these cancers occur during the years after pregnancy, a pattern that is especially pronounced for women at high genetic risk. With roughly one in eight women in Canada developing breast cancer over their lifetime, the researchers argue that new prevention strategies are urgently needed. Current options for high-risk women, such as hormone-blocking therapy or prophylactic surgery, can carry significant physical and emotional burdens, and many women at risk delay or avoid them precisely because of those costs. A short course of a well-characterized drug taken after breastfeeding ends would represent a fundamentally gentler intervention.

Study co-lead Dr. Jesús Perez-Losada, a researcher at the Cancer Research Center, a joint institute of the Spanish National Research Council and the University of Salamanca, emphasizes that the post-weaning window is a unique opportunity to target involution directly. He is careful to stress that the strategy is not about changing a woman’s breastfeeding plans: any preventive intervention would be considered only after breastfeeding has ended, leaving the decision about how long to breastfeed entirely with the mother. That framing matters both scientifically and socially, because the intervention exploits a biological process that begins naturally at weaning rather than interfering with lactation itself.

The multinational research team has already secured funding from the Gray Foundation for a clinical trial spanning multiple countries. The trial will recruit women with BRCA1 mutations through high-risk clinics, and participants will choose how long they want to breastfeed. After weaning, they will receive either cabergoline or a placebo while researchers monitor biological markers linked to future breast cancer risk. Because full cancer incidence outcomes would take years to accumulate, the trial is designed to read surrogate markers of risk, such as measures of residual precancerous tissue and involution completeness, which can be assessed far sooner and have been validated in the preclinical work.

The research was funded by the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Research Institute, and Spain’s Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, with additional support from funding agencies in the United Kingdom and the United States. Much remains to be established before cabergoline can be prescribed for prevention: the observational association must survive the scrutiny of a randomized trial, the optimal dose and timing must be defined, and the benefit must be weighed against the drug’s known side-effect profile in this new context. But if the trial confirms what the population data and mouse models suggest, the field would gain something it has rarely had: a prevention strategy timed to a specific, well-understood biological window, built on a drug that has been in clinical use for decades. For the women at highest risk, that could mean the difference between watching and waiting after childbirth and taking a concrete, evidence-based step to lower the odds of a disease that strikes hardest in the years when they are raising the children it followed.

Subject of Research: Postpartum breast cancer prevention using the lactation drug cabergoline to enhance mammary gland involution

Article Title: Lactation drug could reduce breast cancer risk after childbirth, study suggests

Article References: Lactation drug could reduce breast cancer risk after childbirth, study suggests. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, cabergoline, postpartum, involution, BRCA1, TP53, lactation suppression, cancer prevention, clinical trial, Cancer Discovery, mammary gland, high-risk women